Oystein Soug
Chief Executive Officer Oncoinvent AS
Oystein Soug has served as CEO of clinical-stage radiopharmaceutical company Oncoinvent since 2024, leading the company’s Phase 2 development of alpha-emitting radiopharmaceuticals for cancer that have spread to the abdominal cavity. Prior to joining Oncoinvent, he was CEO of Calluna Pharma (previous Arxx Therapeutics) and Circio (previous Targovax). Earlier in his career, Mr. Soug served as CFO of Oslo-listed radiopharmaceutical company Algeta, where he played a key role in the company’s growth and commercialization journey. During his tenure, Algeta successfully launched and completed its Phase 3 trial, launched the radium-223 therapy Xofigo® for prostate cancer, and entered into a strategic commercialization partnership. He later co-led the sale of Algeta to Bayer for USD 3bn. Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen, Switzerland.
Seminars
- Evaluating which early clinical signals and development opportunities demonstrate sufficient clinical and commercial potential to justify progression into resource-intensive Phase II–III trials
- Assessing efficacy, safety, patient selection and competitive differentiation to distinguish programmes capable of delivering meaningful value from those entering increasingly crowded RLT landscapes
- Leveraging clinical data, competitive intelligence and evolving market dynamics to inform late-stage portfolio and investment decisions and prioritise the RLT programmes with the strongest path towards registration
